P508 Drug survival and reasons for discontinuation of anti-TNF therapy in inflammatory bowel disease (IBD) in clinical practice

Gisbert, J.P.; Arredondo, Miguel; Chaparro, María; Cañamares, I.; Daudén, E.; Fernández-Jiménez, Guillermo; Meca, V.; Morell, A.; Carmona, Lucero; Alvaro-Gracia, J. M.

doi:10.1016/s1873-9946(14)60628-0

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 54 Since it is derived from animal antibodies, its administration comes with a higher risk of allergic reaction 55 and a loss of response due to anti-IFX antibodies, which may lead to treatment discontinuation. 82 …”

Section: Pathogenic Factorsmentioning

confidence: 99%

Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets

Manuc¹,

Manuc²,

Diculescu³

2016

CEG

View full text Add to dashboard Cite

Chronic inflammatory bowel diseases (IBDs) are a subject of great interest in gastroenterology, due to a pathological mechanism that is difficult to explain and an optimal therapeutic approach still undiscovered. Crohn’s disease (CD) is one of the main entities in IBD, characterized by clinical polymorphism and great variability in the treatment response. Modern theories on the pathogenesis of CD have proven that gut microbiome and environmental factors lead to an abnormal immune response in a genetically predisposed patient. Genome-wide association studies in patients with CD worldwide revealed several genetic mutations that increase the risk of IBD and that predispose to a more severe course of disease. Gut microbiota is considered a compulsory and an essential part in the pathogenesis of CD. Intestinal dysmicrobism with excessive amounts of different bacterial strains can be found in all patients with IBD. The discovery of Escherichia coli entero-invasive on resection pieces in patients with CD now increases the likelihood of antimicrobial or vaccine-type treatments. Recent studies targeting intestinal immunology and its molecular activation pathways provide new possibilities for therapeutics. In addition to antitumor necrosis factor molecules, which were a breakthrough in IBD, improving mucosal healing and resection-free survival rate, other classes of therapeutic agents come to focus. Leukocyte adhesion inhibitors block the leukocyte homing mechanism and prevent cellular immune response. In addition to anti-integrin antibodies, chemokine receptor antagonists and SMAD7 antisense oligonucleotides have shown encouraging results in clinical trials. Micro-RNAs have demonstrated their role as disease biomarkers but it could also become useful for the treatment of IBD. Moreover, cellular therapy is another therapeutic approach under development, aimed for severe refractory CD. Other experimental treatments include intravenous immunoglobulins, exclusive enteral nutrition, and granulocyte colony-stimulating factors.

show abstract

Section: Pathogenic Factorsmentioning

confidence: 99%

Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets

Manuc¹,

Manuc²,

Diculescu³

2016

CEG

View full text Add to dashboard Cite

show abstract

“…In addition, real life evidence demonstrates that drug survival is rather low, in most cases due to efficacy issues, i.e. primary and secondary non-response [8][9][10][11][12][13][14][15][16]. Primary non-response (PNR) is the inability to respond to therapy in the induction phase whereas secondary non-response (SNR) can be defined as loss of response after initial clinical benefit.…”

Section: Introductionmentioning

confidence: 99%

Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey

Schots

Grine

Soenen

et al. 2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Background: Therapeutic drug monitoring (TDM) may lead to more rational use of biologics. Still, TDM is largely underexplored in psoriasis. Little is known about the dosing behavior of biologics by dermatologists, and their attitude towards TDM.Objective: Exploration of the awareness and need for the concept of TDM in psoriasis amongst (inter)national dermatologists. Method: A survey was distributed at the Belgian Dermatology Days 2019 and Skin Inflammation & Psoriasis International Network (SPIN) Congress 2019. Next, an online survey version was launched amongst the SPIN Scientific Committee members. We collected physician's characteristics, prescription behavior of biologics, data regarding clinical response to biologics and attitude towards TDM. Results: A total of 107 surveys were included for analysis. Most dermatologists were Belgium-based (54.2%), others from European (23.4%) or non-European countries (19.6%).Seventy percent performed either dose increase (64.8%), time interval shortening (74.6%), dose lowering (16.9%) or time interval extension (33.8%). The majority who performed dose adaptations acknowledged the need for TDM. Conclusion:This study showed most dermatologists perform dose adaptations empirically.The need for TDM was indicated by the majority, implying the need for effective communication regarding availability, utility and implementation of TDM assays in daily dermatology practice.

show abstract

P508 Drug survival and reasons for discontinuation of anti-TNF therapy in inflammatory bowel disease (IBD) in clinical practice

Cited by 2 publications

References 0 publications

Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets

Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets

Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey

Contact Info

Product

Resources

About

P508 Drug survival and reasons for discontinuation of anti-TNF therapy in inflammatory bowel disease (IBD) in clinical practice

Cited by 2 publications

References 0 publications

Recent insights into the molecular pathogenesis of Crohn&#39;s disease: a review of emerging therapeutic targets

Recent insights into the molecular pathogenesis of Crohn&#39;s disease: a review of emerging therapeutic targets

Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey

Contact Info

Product

Resources

About

Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets

Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets